Recently IND-Cleared HER2 × CD3 T-Cell Engager Highlighted by Global Biopharmaceutical PartnerBURLINGTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP), a clinical-stage biotechnology company developing next-generation antibody therapeutics for solid tumors, today announced that its lead multispecific antibody oncology program, ABP-102 / CT-P72, was featured in a presentation by its global collaboration partner, Celltrion, at the 2026 J.P. Morgan Healthcare Conference. Celltrio ...

BURLINGTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP), a clinical-stage biotechnology company developing next-generation antibody therapeutics for solid tumors, today announced that its lead multispecific antibody oncology program, ABP-102 / CT-P72, was featured in a presentation by its global collaboration partner, Celltrion, at the 2026 J.P. Morgan Healthcare Conference. Celltrion’s senior executives attended the conference to present the company’s latest progress in new ...

FDA clearance enables initiation of Abpro’s first clinical-stage solid tumor program Clinical trial anticipated to commence in the first half of 2026 through Abpro’s global collaboration with Celltrion BURLINGTON, Mass. and INCHEON, South Korea, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP), a biotechnology company developing next-generation antibody therapeutics for solid tumors, today announced, together with its co-development partner Celltrion, Inc., that the U.S. Food and Drug Ad ...

 IND submitted for ABP-102/CT-P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable safety profile ABP-102/CT-P72 represents Abpro’s first IND submission for a phase 1 trial in a solid tumor indication, and is being co-developed by Abpro and Celltrion, Inc. BURLINGTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP, “Abpro”), a biotechnology company developing novel breakthrough therapeutics for solid tumors, ...

Core Insights - Abpro Holdings, Inc. has received an extension from the Nasdaq Hearings Panel to regain compliance with Nasdaq listing requirements, indicating progress in its turnaround strategy and pipeline advancement [1][2] Compliance and Financial Strategy - The company has implemented a reverse stock split and is pursuing a market transfer application as part of its compliance roadmap [2] - Abpro has access to up to $44 million in equity financing to support operations and achieve long-term financial goals [2][6] Operational Efficiency - Abpro has achieved an estimated 60% reduction in operating expenses compared to the previous year through disciplined streamlining [6] Pipeline Development - The lead antibody candidate, ABP-102, is on track for first-in-human trials in 2026, developed in partnership with Celltrion [6] - The company is advancing its proprietary DiversImmune and MultiMab™ platforms to enhance the selectivity and safety profiles of its antibody therapies [6] Management Perspective - The CEO of Abpro emphasized the importance of the extension for continuing the compliance plan and executing the company's strategy for sustainable growth [2][4]

As filed with the U.S. Securities and Exchange Commission on November 28, 2025 Registration No. 333-291347 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Abpro Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 87-1013956 (I.R.S. Employer Identificat ...

As filed with the U.S. Securities and Exchange Commission on November 28, 2025 Registration No. 333-291347 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 87-1013956 (I.R.S. Employer Identification No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Abpro Holdings, Inc. (Exact Name of Registrant as Specified in its ...

As filed with the U.S. Securities and Exchange Commission on November 7, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Abpro Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) (Primary Standard Industrial Delaware 2834 87-1013956 (I.R.S. Employer Identification No.) (State or other jurisdiction of incorporation or organization) Classification Code Number) 100 Summit Drive ...

As filed with the U.S. Securities and Exchange Commission on November 7, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Abpro Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) (Primary Standard Industrial Delaware 2834 87-1013956 (I.R.S. Employer Identification No.) (State or other jurisdiction of incorporation or organization) Classification Code Number) 100 Summit Drive ...

Core Insights - Abpro Holdings, Inc. has implemented a 1-for-30 reverse stock split to maintain compliance with Nasdaq and position the company for future growth [1][4] - The company has achieved approximately 60% reduction in operating costs compared to the same period in 2024 through a focused cost optimization plan [1][4] - Abpro's partnership with Celltrion is a strategic advantage, as Celltrion funds all development expenses for Abpro's lead antibody program ABP-102, with a first-in-human trial anticipated in 2026 [5][4] Company Actions - The reverse stock split became effective on October 31, 2025, reducing the number of outstanding shares from approximately 81.2 million to 2.7 million [2] - The company's transfer agent, Continental Stock Transfer & Trust Company, will act as the exchange agent for the reverse stock split [3] Strategic Positioning - Abpro is focused on unlocking additional value through its DiversImmune® and MultiMabTM platforms, which facilitate the rapid creation of bispecific and multispecific antibodies [6] - The company aims to create long-term value for shareholders by executing more effectively with a leaner cost structure and a major global partner [4] Company Overview - Abpro is dedicated to improving lives through next-generation antibody therapies targeting severe diseases, utilizing its proprietary DiversImmune® platform [7]